Bevacizumab News and Research

RSS
Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
SARS-CoV-2 spike protein may induce analgesia

SARS-CoV-2 spike protein may induce analgesia

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

COVID-19 clinical trials show positive early results, says GlobalData

COVID-19 clinical trials show positive early results, says GlobalData

New treatment improves survival for people with common liver cancer

New treatment improves survival for people with common liver cancer

A faster and easier treatment option to prevent blindness in preterm infants

A faster and easier treatment option to prevent blindness in preterm infants

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

Study may provide novel targetable mechanisms of therapeutic resistance to anti-VEGF therapies

Study may provide novel targetable mechanisms of therapeutic resistance to anti-VEGF therapies

Maintenance chemotherapy after initial treatment more beneficial for metastatic colorectal cancer patients

Maintenance chemotherapy after initial treatment more beneficial for metastatic colorectal cancer patients

Combination therapy improves survival in patients with hepatocellular carcinoma

Combination therapy improves survival in patients with hepatocellular carcinoma

NCCN ORP plans to support phase II randomized trial for lung cancer patients

NCCN ORP plans to support phase II randomized trial for lung cancer patients

Intensive new combination therapy for ovarian cancer shows promising results

Intensive new combination therapy for ovarian cancer shows promising results

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

Scientists use advanced imaging to track brain tumor 'turncoats'

Scientists use advanced imaging to track brain tumor 'turncoats'

Identifying colorectal cancer subtypes in patients could help provide better care

Identifying colorectal cancer subtypes in patients could help provide better care

Identifying subtype of colorectal cancer may help oncologists determine most effective treatment

Identifying subtype of colorectal cancer may help oncologists determine most effective treatment

New study finds almost 400 established medical practices that don’t work

New study finds almost 400 established medical practices that don’t work

New analysis reveals precision oncology insights for colorectal cancer

New analysis reveals precision oncology insights for colorectal cancer

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress